Idiopathic pulmonary fibrosis is a chronic progressive fibrosing interstitial lung disease of unknown cause characterized by worsening dyspnea, cough, and declining lung function. It primarily affects older adults and has a poor prognosis despite available antifibrotic therapies. Diagnosis typically requires multidisciplinary evaluation and exclusion of secondary causes.
Insmed reported Q2 2026 revenues of $425.5M, with BRINSUPRI at $309.2M. It raised 2026 BRINSUPRI guidance to $1.25B-$1.40B and lifted peak revenue estimates for its lead programs to over $14B.
PureTech Health's IPF drug deupirfenidone received orphan drug designation from the FDA and European Commission. The designation provides market exclusivity and financial incentives. A phase 3 trial is expected to begin in the first half of 2026.
GRI Bio discussed positive Phase 2a idiopathic pulmonary fibrosis data for GRI-0621, highlighting biomarker results indicating improvements in fibrosis and lung repair.
The FDA has granted orphan drug designation to Nuformix PLC's tranilast lysate candidate for treating idiopathic pulmonary fibrosis. The designation provides regulatory incentives including potential market exclusivity in the US. Nuformix is a London-based developer focused on fibrosis and oncology treatments.
Deupirfenidone, a deuterated form of pirfenidone, is set to be tested in a phase 3 trial this year after successful phase 2b results. The FDA and European Commission have granted orphan drug designation to support its late-stage development.
Bristol Myers Squibb's growth portfolio increased 17% in 2025, partially offsetting a 15% decline in legacy products facing generic competition. The company's stock gained 11.4% in the past month on strong fourth-quarter results.
Insmed reported total revenues of $606.4 million for 2025, with ARIKAYCE growing 19% annually. The FDA granted orphan drug designation to treprostinil palmitil for pulmonary arterial hypertension treatment in January 2026.
PureTech Health announced that deupirfenidone has received Orphan Drug Designation from both the U.S. FDA and European Commission for idiopathic pulmonary fibrosis, with a Phase 3 trial planned for the first half of 2026.
PureTech Health's deupirfenidone has received Orphan Drug Designation from both the U.S. FDA and European Commission for treating idiopathic pulmonary fibrosis, a rare and fatal lung disease. Phase 2b trial results showed superior efficacy compared to existing therapies.
AbbVie reported progress on two clinical studies: a Phase 2a trial of ABBV-142 for idiopathic pulmonary fibrosis now recruiting patients, and completion of a JUVÉDERM VOLITE study for facial skin quality improvement.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07743996 |
Emotional and Social Experiences of Antifibrotic (AF) Therapy Among Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF) Patients: A Real-World Study |
RECRUITING | |
| NCT07728448 |
Predictors of Pulmonary Embolism in Interstitial Lung Disease With Worsening Symptoms |
NOT_YET_RECRUITING | |
| NCT07723638 |
New Diagnostic Approaches in the Management of Inflammatory Lung Diseases |
NOT_YET_RECRUITING | NA |
| NCT07722507 |
Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis |
NOT_YET_RECRUITING | |
| NCT07712952 |
Validation of AI-Based Detection of Idiopathic Pulmonary Fibrosis in Serial Chest Radiographs: A Retrospective Longitudinal Study |
COMPLETED | |
| NCT07687459 |
Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07682337 |
Study of Single and Multiple Oral Doses of SCB0020160 in Healthy Adult Male Subjects |
NOT_YET_RECRUITING | PHASE1 |
| NCT07679893 |
Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis |
RECRUITING | PHASE2 |
| NCT07674745 |
Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis |
NOT_YET_RECRUITING | PHASE2 |
| NCT07671911 |
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets |
RECRUITING | PHASE3 |
